



Hyderabad, 1<sup>st</sup> March, 2014

**NATCO Comments on Decision by New Delhi High Court Against Teva**

Natco Pharma Ltd. today commented on the New Delhi High Court's decision to dismiss a lawsuit related to applications filed by Teva Pharmaceuticals Industries Ltd., Yeda Research and Development Co. Ltd. and Teva API India Limited ("Teva"). Teva had alleged that Natco's use in India of the well-known process to manufacture copolymer-1 infringes Yeda's Indian Patent No. 190759 ("IN'759").

Natco commented, "We are very pleased with the decision by the New Delhi High Court to dismiss and take no action in this matter. We continue to believe that the sole Indian process patent is invalid, as reinforced by the outcomes of numerous other legal proceedings. We also are pursuing other challenges against this patent."

In addition to defending against Teva's actions in the New Delhi High Court, the company is pursuing other challenges against the IN'759 patent, including a petition to the New Delhi High Court to invalidate the patent. The hearing on this petition has been set for 5 March 2014. Further, the Indian Patent Office refused to grant two additional patent applications, which would have covered the copolymer-1 product.

The U.S. counterpart to the IN'759 patent, U.S. Patent No. 5,800,808, along with four other U.S. patents, was held to be invalid by the U.S. Court of Appeals for the Federal Circuit last July. All of Teva's further appellate attempts have been unsuccessful to date.

---

Forwarded for favor of publication  
For NATCO Pharma Limited

*M Adinarayana*

M Adinarayana  
Company Secretary &  
Vice President (Legal & Corp Affairs)